Media Newsroom of

Alpha Cancer Technologies Inc.

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with products under development in oncology and auto-immune disease indications that use our proprietary recombinant human Alpha Fetoprotein (AFP).

Study Results of ACT-101 in a Model of Inflammatory Bowel Disease (IBD) Presented at the World Congress of Gastroenterology 2017

Study Results of ACT-101 in a Model of Inflammatory Bowel Disease (IBD) Presented at the World Congress of Gastroenterology 2017

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on therapies for patients with autoimmune diseases and cancer, today announced the results of a study of ACT-101 (recombinant human alpha fetoprotein or rhAFP) in the treatment of Inflammatory Bowel Disease…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login